Idexx Laboratories Inc Revenue Growth Rates (IDXX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Idexx Laboratories Inc  (NASDAQ: IDXX)
 

IDXX's Revenue Growth by Quarter and Year

Idexx Laboratories Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IDXX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1,216.59
1st Quarter March 1,140.74
FY 2,357.33

IDXXs Annual Revenue
Idexx Laboratories Inc's Revenue in the fiscal year 2025 $ 4,303.58 millions
Idexx Laboratories Inc's Revenue in the fiscal year 2024 $ 3,896.93 millions
Idexx Laboratories Inc's Revenue in the fiscal year 2023 $ 3,659.97 millions
Idexx Laboratories Inc's Revenue in the fiscal year 2022 $ 3,367.32 millions
Idexx Laboratories Inc's Revenue in the fiscal year 2021 $ 3,215.36 millions




IDXX Revenue second quarter 2026 Y/Y Growth Comment
Idexx Laboratories Inc reported Revenue growth of 9.73% year on year in the second quarter 2026, to $ 1,216.59 millions, this is lower than Idexx Laboratories Inc's recent average Revenue growth of 9.78%.

Looking into second quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 5 other companies have achieved higher Revenue growth. While Idexx Laboratories Inc' s Revenue increase of 9.73% ranks overall at the positon no. 2290 in the second quarter 2026.


IDXX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 14.4 % 5.94 % 8.76 %
3rd Quarter September - 13.26 % 6.56 % 8.71 %
2nd Quarter June 9.73 % 10.52 % 6.31 % 9.65 %
1st Quarter March 14.26 % 3.56 % 7.1 % 7.61 %
FY   - 10.43 % 6.47 % -

Financial Statements
Idexx Laboratories Inc's second quarter 2026 Revenue $ 1,216.59 millions IDXX's Income Statement
Idexx Laboratories Inc's second quarter 2025 Revenue $ 1,108.73 millions Quarterly IDXX's Income Statement


IDXX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -1.11 % -2.09 % -1.51 %
3rd Quarter September - -0.4 % -2.8 % -3.04 %
2nd Quarter June 6.65 % 11.05 % 4.05 % 4.82 %
1st Quarter March 4.45 % 4.58 % 6.98 % 8.65 %
FY (Year on Year)   - 10.43 % 6.47 % -


Back to IDXX Growth rate Comparisons >> Back to IDXX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #333
Overall #2290

Revenue Y/Y Growth Statistics
High Average Low
23.11 % 9.78 % 4.45 %
(Jun 30 2021)   (Sep 30 2015)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #333
Overall #2290
Revenue Y/Y Growth Statistics
High Average Low
23.11 % 9.78 % 4.45 %
(Jun 30 2021)   (Sep 30 2015)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Idexx Laboratories Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
13.21 % 2.39 % -8.23 %
(Sep 30 2020)  


IDXX's II. Quarter Q/Q Revenue Comment
Idexx Laboratories Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 6.65%, to $ 1,216.59 millions, from $1,140.74 millions in the first quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Idexx Laboratories Inc's Revenue growth quarter on quarter, overall rank is 994.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #150
Overall #994
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #150
Overall #994
Revenue Q/Q Growth Statistics
High Average Low
13.21 % 2.39 % -8.23 %
(Sep 30 2020)  


IDXX's II. Quarter Q/Q Revenue Comment
Idexx Laboratories Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 6.65%, to $ 1,216.59 millions, from $1,140.74 millions in the first quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Idexx Laboratories Inc's Revenue growth quarter on quarter, overall rank is 994.


Idexx Laboratories Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 4,553.79 $ 4,445.94 $ 4,303.58 $ 4,166.13 $ 4,036.81
Y / Y Revenue Growth (TTM) 12.81 % 13.09 % 10.44 % 8.4 % 6.7 %
Year on Year Revenue Growth Overall Ranking # 1839 # 1253 # 1099 # 679 # 501
Seqeuential Revenue Change (TTM) 2.43 % 3.31 % 3.3 % 3.2 % 2.69 %
Seq. Revenue Growth (TTM) Overall Ranking # 2290 # 1619 # 1526 # 1871 # 1846


Cumulative Revenue growth Comment
Assuming the Idexx Laboratories Inc's fiscal year would have ended in Jun 30 2026, Idexx Laboratories Inc would have reprted above average annual Revenue increase of 12.81% year on year, of $ 4,554 millions.
This marks a slow-down of the companys growth trends and from the 13.09% rise in Mar 31 2026.

In the Healthcare sector 288 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1253 to 1839.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 6
Healthcare Sector # 289
Overall # 1839

Revenue TTM Y/Y Growth Statistics
High Average Low
23.11 %
 9.78 %
4.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 333
S&P 500 # 2290
Cumulative Revenue growth Comment
Assuming the Idexx Laboratories Inc's fiscal year would have ended in Jun 30 2026, Idexx Laboratories Inc would have reprted above average annual Revenue increase of 12.81% year on year, of $ 4,554 millions.
This marks a slow-down of the companys growth trends and from the 13.09% rise in Mar 31 2026.

In the Healthcare sector 288 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1253 to 1839.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 6
Healthcare Sector # 289
Overall # 1839

Revenue TTM Y/Y Growth Statistics
High Average Low
23.11 %
9.78 %
4.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 333
S&P 500 # 2290




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IDXX's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Cvrx inc 16.77%$ 16.766 millions
Regeneron Pharmaceuticals Inc 16.73%$ 16.735 millions
Invo Fertility Inc 16.73%$ 16.732 millions
Pro dex Inc 16.65%$ 16.646 millions
Royalty Pharma Plc16.50%$ 16.499 millions
Acadia Pharmaceuticals Inc 16.40%$ 16.402 millions
Harvard Bioscience Inc 16.35%$ 16.352 millions
Alpha Pro Tech Ltd 15.76%$ 15.765 millions
Armata Pharmaceuticals Inc 15.72%$ 15.722 millions
Lifeward ltd 15.71%$ 15.706 millions
Novocure Limited15.60%$ 15.603 millions
Ufp Technologies Inc 15.56%$ 15.558 millions
Orthopediatrics Corp15.55%$ 15.551 millions
Jazz Pharmaceuticals Plc15.55%$ 15.548 millions
Alphatec Holdings Inc 15.35%$ 15.349 millions
Penumbra Inc14.90%$ 14.904 millions
Rockwell Medical inc 14.69%$ 14.687 millions
Sbc Medical Group Holdings Incorporated14.36%$ 14.363 millions
Nuwellis Inc 14.14%$ 14.145 millions
West Pharmaceutical Services Inc 13.89%$ 13.892 millions
Edwards Lifesciences Corporation13.66%$ 13.657 millions
Indivior Pharmaceuticals Inc 13.58%$ 13.576 millions
Talkspace Inc 13.56%$ 13.556 millions
Atricure Inc 13.38%$ 13.376 millions
Dexcom Inc 13.11%$ 13.105 millions
Sanara Medtech Inc 13.03%$ 13.028 millions
Bausch Health Companies Inc 12.73%$ 12.727 millions
Vertex Pharmaceuticals Inc12.45%$ 12.453 millions
Genedx Holdings Corp 12.30%$ 12.304 millions
Profound Medical Corp 12.30%$ 12.302 millions


About Idexx Laboratories Inc Revenue Growth Rates (IDXX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Idexx Laboratories Inc (CIK 874716).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000874716-26-000123
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Idexx Laboratories Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.